Clinical trials: Upper Extremity Weakness

Thymidine Kinase 2 Deficiency

A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)

• Withdrawn
• Age: Up to 18 years
• Phase 3

This is a Phase 3b, prospective, single-arm, multicenter, open-label treatment study of the efficacy and safety of MT1621 in pediatric and adolescent patients with thymidine kinase 2 deficiency (TK2d).

Trial name

NCT04581733

Testing

MT1621

Sponsor

Zogenix MDS, Inc.